50 / 68
228
Ces Urol 2016; 20(3): 221–228
ORIGINÁLNÍ PRÁCE
3. Meeks JJ, Bellmunt J, Bochner BH, et al.
A systematic review of neoadjuvant and adjuvant chemothe‑
rapy for muscle-invasive bladder cancer. Eur Urol 2012; 62: 523–533.
4.
Advanced Bladder Cancer (ABC) Meta-Analysis Collaboration: Neoadjuvant chemotherapy in invasive
bladder cancer: update of a systematic review and meta-analysis of individual patient data: advanced
bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48: 202–205.
5. Lavery HJ, Stensland KD, Niegisch G, Albers P, Droller MJ.
Pathological T0 following radical cystectomy
with or without neoadjuvant chemotherapy: a useful surrogate. J Urol. 2014; 191(4): 898–906.
6. Culp SH, Dickstein RJ, Grossman HB, et al.
Refining patient selection for neoadjuvant chemotherapy
before radical cystectomy. J Urol. 2014; 191(1): 40–47.
7. Lotan Y, Gupta A, Shariat SF, et al.
Lymphovascular invasion is independently associated with overall
survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes
at radical cystectomy. J Clin Oncol 2005; 23(27): 6533–6539.
8. Stimson CJ, Cookson MS, Barocas DA, et al.
Preoperative hydronephrosis predicts extravesical and
node positive disease in patients undergoing cystectomy for bladder cancer. J Urol. 2010; 183(5): 1732–1737.
9. Petrelli F, Coinu A, Cabiddu M, et al.
Correlation of pathologic complete response with survival after
neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol 2014;
65(2): 350–357.
10. Gandhi NM, Baras A, Munari E, et al.
Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle‑
-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urol Oncol 2015; 33(5): 204e1–7.
11. Grossman HB, Natale RB, Tangen CM, et al.
Neoadjuvant chemotherapy plus cystectomy compared
with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349: 859–866.
12. Sherif A, Holmberg L, Rintala E, et al.
Neoadjuvant cisplatinum based combination chemotherapy in
patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 2004; 45: 297–303.
13. Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK.
International phase III trial assessing neoadju‑
vant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term
results of the BA06 30894 trial. J Clin Oncol 2011; 29(16): 2171–2177.
14. Zarger H, Espiritu PN, Fairey AS, et al.
Multicenter assessment of neoadjuvant chemotherapy for
muscle-invasive bladder cancer. Eur Urol 2015; 67(2): 241–249.
15. Von der Maase H, Sengelov L, Roberts JT, et al.
Long-term survival results of a randomized trial com‑
paring gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients
with bladder cancer. J Clin Oncol 2005; 23: 4602–4608.
16. Herr HW, Faulkner JR, Grossman HB, et al.
Surgical factors influence bladder cancer outcomes: a co‑
operative group report. J Clin Oncol 2004; 22(14): 2781–2789.
17. Nuhn P, May M, Fritsche H-M, et al.
External validation of disease-free survival at 2 or 3 years as a su‑
rrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma
of the bladder. Eur J Surg Oncol 2012; 38: 637–642.
18. Plimack ER, Dunbrack RL, Brennan TA, et al.
Defects in DNA repair genes predict response to neo‑
adjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 2015; 68(6): 959–967.
19. Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of urothelial
bladder carcinoma. Nature. 2014; 507: 315–322.